SCHEMBL23258016

SCHEMBL23258016

CS(=O)(=O)C1CCN(c2nc(CCCN[C@@H]3C[C@H]3c3ccc(F)cc3)c[nH]c2=O)CC1

nearest known ligand 0.45

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 20/20 0.45
HDAC6 Q9UBN7 6/20 0.41
MAOB P27338 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21553115 0.89 KDM1A (0.49) KDM1AHDAC6
SCHEMBL26037108 0.88 KDM1A (0.41) KDM1AHDAC6MAOB
SCHEMBL21553017 0.88 KDM1A (0.46) KDM1AHDAC6MAOB
SCHEMBL26031623 0.87 KDM1A (0.44) KDM1AHDAC6MAOB
SCHEMBL21552936 0.87 KDM1A (0.46) KDM1AHDAC6MAOB
SCHEMBL21552995 0.87 KDM1A (0.46) KDM1AHDAC6MAOB
SCHEMBL21552880 0.86 KDM1A (0.44) KDM1AHDAC6
SCHEMBL21552961 0.86 KDM1A (0.45) KDM1AHDAC6
SCHEMBL21553112 0.86 KDM1A (0.42) KDM1AHDAC6
SCHEMBL26033712 0.86 KDM1A (0.42) KDM1AHDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11578059-B2 KDM1A inhibitors for the treatment of disease Imago Biosciences. Inc. (US) 2023-02-14 US disclosed
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. 2021-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210115023-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1A, KDM1B, KDM2A KDM1A 1/4885HDAC6 1998/4885MAOB 2956/4885
US-11578059-B2 KDM1A inhibitors for the treatment of disease KDM1B, KDM1A, KDM2A KDM1A 2/4885HDAC6 2063/4885MAOB 3342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.